Hims is a telehealth company offering discreet virtual consultations and prescription delivery for men's health concerns. Hims' hair loss program uses FDA-approved treatments like finasteride and ...

NEW YORK and NEW ORLEANS, March 20, 2026 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that ...

NEW YORK, March 2 (Reuters) - Telehealth company Hims & Hers Health (HIMS.N), opens new tab, known for its weight-loss drug business, is promising it can diversify away from its reliance on compounded ...

A pending FDA review of several peptides is giving investors a new growth story for Hims as the company resets its U.S. weight-loss business.

Hims & Hers faces a pivotal regulatory moment as the FDA reconsiders compounded peptide therapies, especially GLP-1 drugs like semaglutide. A permissive FDA framework could legitimize compounded ...

Hims & Hers Health (NYSE:HIMS) looked like a fallen growth star earlier this year. The telehealth platform was hammered by the FDA’s aggressive crackdown on compounded GLP-1 drugs, complete with ...

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Hims & Hers Health ...